Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company focused on developing off-the-shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells to treat several types of cancer. NK cells are the body’s first line of defense because of the innate ability of NK cells to rapidly and accurately identify and destroy cells under stress, such as cancer or virally infected cells. Glycostem’s lead product, oNKord®, is produced in a closed system in Glycostem’s state-of-the-art production facility in The Netherlands, from which the product can be distributed globally. The platform technology includes ex vivo expansion of a high number of pure and highly activated NK cells for clinical applications. oNKord® successfully concluded Phase I clinical trial (elderly and fragile AML patients), providing solid safety data and strong indication of clinical activity, including response on MRD. Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019. Thanks to the six patent families, longstanding technical expertise and resources, as well as ‘Orphan Drug Designation’, Glycostem has secured a leadership position in the global NK cell market.